Log in

NASDAQ:BLUE - bluebird bio Stock Price, Forecast & News

$84.05
-2.92 (-3.36 %)
(As of 12/13/2019 06:00 AM ET)
Today's Range
$83.78
Now: $84.05
$89.49
50-Day Range
$72.50
MA: $79.42
$87.10
52-Week Range
$71.42
Now: $84.05
$163.43
Volume1.85 million shs
Average Volume1.60 million shs
Market Capitalization$4.65 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.16
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BLUE
CUSIPN/A
Phone339-499-9300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$54.58 million
Book Value$34.47 per share

Profitability

Net Income$-555,630,000.00
Net Margins-1,326.56%

Miscellaneous

Employees764
Market Cap$4.65 billion
Next Earnings Date2/20/2020 (Estimated)
OptionableOptionable

Receive BLUE News and Ratings via Email

Sign-up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter.


bluebird bio (NASDAQ:BLUE) Frequently Asked Questions

What is bluebird bio's stock symbol?

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

How were bluebird bio's earnings last quarter?

bluebird bio Inc (NASDAQ:BLUE) posted its quarterly earnings results on Thursday, October, 31st. The biotechnology company reported ($3.73) EPS for the quarter, missing the consensus estimate of ($3.54) by $0.19. The biotechnology company earned $8.91 million during the quarter, compared to analysts' expectations of $12.47 million. bluebird bio had a negative net margin of 1,326.56% and a negative return on equity of 42.29%. bluebird bio's revenue for the quarter was down 22.7% compared to the same quarter last year. During the same period in the previous year, the company posted ($2.73) earnings per share. View bluebird bio's Earnings History.

When is bluebird bio's next earnings date?

bluebird bio is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for bluebird bio.

What price target have analysts set for BLUE?

19 brokers have issued 1-year target prices for bluebird bio's shares. Their forecasts range from $96.00 to $195.00. On average, they anticipate bluebird bio's share price to reach $136.87 in the next twelve months. This suggests a possible upside of 62.8% from the stock's current price. View Analyst Price Targets for bluebird bio.

What is the consensus analysts' recommendation for bluebird bio?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last year. There are currently 6 hold ratings, 12 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for bluebird bio.

Has bluebird bio been receiving favorable news coverage?

Headlines about BLUE stock have trended positive recently, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. bluebird bio earned a media sentiment score of 2.4 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for bluebird bio.

Are investors shorting bluebird bio?

bluebird bio saw a decline in short interest during the month of November. As of November 29th, there was short interest totalling 8,130,000 shares, a decline of 7.9% from the November 14th total of 8,830,000 shares. Based on an average daily volume of 1,040,000 shares, the days-to-cover ratio is presently 7.8 days. Currently, 14.8% of the company's shares are short sold. View bluebird bio's Current Options Chain.

Who are some of bluebird bio's key competitors?

What other stocks do shareholders of bluebird bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include Opko Health (OPK), BioMarin Pharmaceutical (BMRN), Celgene (CELG), Puma Biotechnology (PBYI), Incyte (INCY), Medivation (MDVN), Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU) and ABIOMED (ABMD).

Who are bluebird bio's key executives?

bluebird bio's management team includes the folowing people:
  • Mr. Nick Leschly, Pres, CEO & Director (Age 46)
  • Mr. Jason F. Cole, Chief Operating & Legal Officer and Sec. (Age 46)
  • Dr. Philip D. Gregory, Chief Scientific Officer (Age 48)
  • Mr. Jeffrey T. Walsh, Chief Strategy Officer (Age 53)
  • Dr. David M. Davidson, Chief Medical Officer (Age 55)

Who are bluebird bio's major shareholders?

bluebird bio's stock is owned by a number of of retail and institutional investors. Top institutional investors include State Street Corp (2.36%), First Trust Advisors LP (0.79%), Nikko Asset Management Americas Inc. (0.29%), Sumitomo Mitsui Trust Holdings Inc. (0.29%), Peregrine Capital Management LLC (0.21%) and California Public Employees Retirement System (0.19%). Company insiders that own bluebird bio stock include Alison Cecily Finger, David Davidson, James Mandell, Jason Cole, Jeffrey T Walsh, Kory James Wentworth, Mark Vachon, Nick Leschly, Philip D Gregory and Susanna Gatti High. View Institutional Ownership Trends for bluebird bio.

Which major investors are selling bluebird bio stock?

BLUE stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Rhenman & Partners Asset Management AB, Voya Investment Management LLC, Gilder Gagnon Howe & Co. LLC, Great West Life Assurance Co. Can, SG Americas Securities LLC, Metropolitan Life Insurance Co NY and Virginia Retirement Systems ET AL. Company insiders that have sold bluebird bio company stock in the last year include David Davidson, Jason Cole, Jeffrey T Walsh, Kory James Wentworth, Nick Leschly and Philip D Gregory. View Insider Buying and Selling for bluebird bio.

Which major investors are buying bluebird bio stock?

BLUE stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Peregrine Capital Management LLC, State of New Jersey Common Pension Fund D, California Public Employees Retirement System, Alberta Investment Management Corp, Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc. and Boussard & Gavaudan Investment Management LLP. View Insider Buying and Selling for bluebird bio.

How do I buy shares of bluebird bio?

Shares of BLUE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is bluebird bio's stock price today?

One share of BLUE stock can currently be purchased for approximately $84.05.

How big of a company is bluebird bio?

bluebird bio has a market capitalization of $4.65 billion and generates $54.58 million in revenue each year. The biotechnology company earns $-555,630,000.00 in net income (profit) each year or ($10.68) on an earnings per share basis. bluebird bio employs 764 workers across the globe.View Additional Information About bluebird bio.

What is bluebird bio's official website?

The official website for bluebird bio is http://www.bluebirdbio.com/.

How can I contact bluebird bio?

bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 339-499-9300 or via email at [email protected]


MarketBeat Community Rating for bluebird bio (NASDAQ BLUE)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  913 (Vote Outperform)
Underperform Votes:  569 (Vote Underperform)
Total Votes:  1,482
MarketBeat's community ratings are surveys of what our community members think about bluebird bio and other stocks. Vote "Outperform" if you believe BLUE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLUE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/13/2019 by MarketBeat.com Staff

Featured Article: What is a conference call?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel